Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Date:3/11/2011

ients greater precision in their efforts to fine tune their glucose control. Patients treated with insulin pumps represent a significant portion of the market, manage their disease aggressively, and are early adopters of new treatments and technologies.
  • Halozyme's two Phase 2 clinical studies that compare treatment with an insulin analog alone to Analog-PH20 for twelve weeks each completed patient enrollment this past January. Results from these two studies will be available to Halozyme internally during the third quarter of 2011.
  • Roche completed patient enrollment of its Phase 3 registration study for Herceptin® SC (trastuzumab subcutaneous) in December for the treatment of HER2-positive breast cancer and has stated it expects to have results from this study by the end of 2011. In February 2011, Roche began patient dosing of the Phase 3 MabThera® SC (rituximab subcutaneous) clinical trial in patients with follicular non-Hodgkin's lymphoma. Roche has stated it expects to file for the approval of Herceptin SC and MabThera SC in the EU during 2012.
  • Baxter completed its Phase 3 clinical trial of HyQ, immunoglobulin with rHuPH20, at the end of 2010. Baxter has stated it plans to submit a BLA filing during the second half of 2011 and to launch the product in 2012. The worldwide market for immunoglobulin totals approximately $6 billion and Baxter commands a sizeable share of the market.

  • Fourth Quarter and Year End 2010 Financial ResultsThe net loss for the fourth quarter of 2010 was $16.9 million, or $0.17 per share, compared with a net loss for the fourth quarter of 2009 of $12.7 million, or $0.14 per share. The net loss for the year ended December 31, 2010 was $53.2 million, or $0.56 per share, compared to a net loss of $58.4 million, or $0.67 per share, for the year 2009.

  • Revenue for the fourth quarter of 2010 was $3.6 million, compared to $6.4 million for the
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
    2. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
    3. Halozyme Therapeutics Realigns Management
    4. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
    5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
    6. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
    7. Halozyme Therapeutics Announces Public Offering of Common Stock
    8. Halozyme Provides HYLENEX® Product Reintroduction Update
    9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
    10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
    11. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
    (Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... for Neurotechnology: 2014-2018" report to their offering. ... the most comprehensive and up-to-date publication available covering the ... the technology, markets, competitors, and growth rates in four ... 2014 through 2018. It forecasts the number of systems ...
    (Date:9/22/2014)... , Sept. 22, 2014 Research ... "PCSK9 and Other Novel Hypercholesterolemia Drugs" report ... that there is a high cholesterol burden despite the ... of all the available options, statins have been ubiquitously ... that reduction of plasma LDL cholesterol (LDLC) is the ...
    Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3The Market for Neurotechnology: 2014-2018 2PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3
    (Date:9/22/2014)... PA (PRWEB) September 22, 2014 The ... in the Greater Philadelphia region each year, is considered ... year, CNC manufacturer MK Precision is proud to announce ... accomplished group. MK Precision will attend the Philadelphia ... one of the premiere business events of the year, ...
    (Date:9/22/2014)... study pulls back the curtain on one of the ... and income between physicians who perform operations, procedures or ... perception, the research indicates, the physician payment system is ... doctors. , The new findings counter the widely held ... explains why doctors who perform procedures often earn nearly ...
    (Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... aware of online physician-rating sites, and more than one-quarter have ... to a new national study. The findings -- based ... that negative online ratings may dissuade parents from choosing a ... neighbor. Conversely, a positive online rating may sway parents ...
    (Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
    (Date:9/22/2014)... 2014. Kessler researchers have published a pilot study ... program in people with multiple sclerosis (MS). ... perceived stress, and pain. "Development and effectiveness ... with MS: Description and outcomes" was epublished ahead ... International Journal of MS Care (doi: 10.7224/1537-2073.2013-045). ...
    Breaking Medicine News(10 mins):Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2
    ... Oct. 21 Today more than ever, employers,are looking ... call for stabilizing influences, and wellness is such an,influence," ... time to put workplace wellness and employee health on ... to begin to realize the financial and,other benefits of ...
    ... celebrates the contributions that pharmacy technicians make on the 18th ... ... Washington, D.C. (PRWEB) October 21, 2008 -- Today marks ... Pharmacy Technician Certification Board (PTCB) applauds the valuable contributions ...
    ... While a poverty-alleviation program launched by the Mexican government ... around the world has led to improved health and ... of California, Berkeley, researchers says that the cash component ... The program, called Oportunidades, provides money to impoverished families ...
    ... Announces It Reduced Debt by $6.1 Million in ... 21 LodgeNet,Interactive Corporation (Nasdaq: LNET ), ... hospitality and healthcare businesses, today,announced that it will ... Tuesday, October 28, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGO ...
    ... Inc. (OTC,Bulletin Board: VSPC) subsidiary Ionfinity has ... its proposal entitled "Miniature Electronic Sniffer,for Navy ... by the Navy,s,Small Business Technology Transfer (STTR) ... result in a field demonstration of high,sensitivity ...
    ... ProLindac Is Safe And Active in Recurrent Ovarian ... DALLAS, Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin ... recent results of the company,s proprietary polymer DACH,platinum ... being,presented this week at a major international oncology ...
    Cached Medicine News:Health News:Even During Financial Crisis Investing in Wellness is Good Business 2Health News:National Pharmacy Technician Day Celebrated with Focus on Quality -- Pharmacy Technician Certification Board (PTCB) Touts Importance of Certified Technicians 2Health News:National Pharmacy Technician Day Celebrated with Focus on Quality -- Pharmacy Technician Certification Board (PTCB) Touts Importance of Certified Technicians 3Health News:Extra cash from government program linked to higher risk of adult obesity 2Health News:Extra cash from government program linked to higher risk of adult obesity 3Health News:LodgeNet Interactive to Report Third Quarter Results on October 28th 2Health News:VIASPACE Subsidiary Wins $786,000 U.S. Navy Contract 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: